Purchase this article with an account.
Jingyuan Zhu, Anoop Sainulabdeen, Krystal Akers, Vishnu Adi, Jeffrey R. Sims, Eva Yarsky, Yi Yan, Yu Yu, Hiroshi Ishikawa, Christopher Kai-Shun Leung, Gadi Wollstein, Joel S Schuman, Wenbin Wei, Kevin Chan; Oral scutellarin treatment preserves retinal structure and visual function in glaucomatous neurodegeneration. Invest. Ophthalmol. Vis. Sci. 2021;62(8):2386.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Intraocular pressure (IOP) is currently the only modifiable risk factor for glaucoma, yet glaucoma can continue to progress despite controlled IOP. Thus, development of glaucoma neurotherapeutics remains an unmet need. Scutellarin is a flavonoid that exhibits a number of neuroprotective effects on the brain and the eye. Here, we investigated the neurobehavioral effects of oral scutellarin treatment in a novel experimental model of chronic glaucoma.
Ten adult C57BL/6J mice (Group 1) were unilaterally injected with an optically clear hydrogel into the anterior chamber to obstruct aqueous outflow and induce chronic IOP elevation. Eight other mice (Group 2) received a unilateral intracameral injection of phosphate-buffered saline only. Another eight mice (Group 3) with hydrogel-induced unilateral chronic IOP elevation also received daily oral gavage of 300 mg/kg scutellarin from 1 week before to 2 weeks after hydrogel injection. Tonometry, optical coherence tomography, and optokinetic visuobehavioral testing were performed longitudinally to monitor the IOP, total retinal thickness, visual acuity, and contrast threshold of bilateral eyes in all three groups.
Intracameral hydrogel injection resulted in unilateral chronic IOP elevation with no significant IOP difference between scutellarin treatment and untreated groups (Figure 1). With scutellarin treatment, the hydrogel-injected eyes showed less retinal thinning and reduced visual behavioral deficits when compared to the untreated, hydrogel-injected eyes (Figure 2). No significant difference in retinal thickness or optokinetic measures was found in the non-injected eyes over time or between all groups.
Oral scutellarin treatment appeared to preserve retinal structure and visual function in experimental glaucoma induced by chronic IOP elevation. Scutellarin may be a possible candidate as a novel neurotherapeutic agent for glaucoma treatment.
This is a 2021 ARVO Annual Meeting abstract.
This PDF is available to Subscribers Only